Machine Learning in Healthcare: Benefits, Use Cases, and Challenges

The 2020s have marked a period of fundamental reconfiguration of healthcare systems under the influence of the dynamic development of artificial intelligence (AI), and in particular its subdiscipline of machine learning (ML). The accelerating integration of these technologies into everyday clinical practice — especially visible between 2021 and 2025 — has produced over 53,000 scientific publications analyzing applications of deep learning (DL) and ML across nearly every medical specialty, from oncology to infectious disease.

This phenomenon is not merely the result of technological progress, but the outcome of a synergy between growing availability of multidimensional medical data, increased computational power, and an urgent need to address systemic problems such as aging populations, rising treatment costs, and a crisis of professional burnout among medical staff.

Contemporary data-driven medicine is evolving toward a predictive and personalized model. Traditional methods of collecting and interpreting health data are being systematically supplemented by algorithms capable of detecting patterns invisible to the human eye, enabling a shift from reactive to proactive medicine.

The central mission of this transformation is not only to improve diagnostic precision but also to democratize access to high-quality care through the automation of routine tasks and real-time support for clinical decision-making.

TL;DR

• Between 2021 and 2025, AI and ML became structurally embedded in healthcare, supported by the growth of multidimensional medical data, stronger computing capacity, and pressure from aging populations, rising costs, and staff burnout. This shift is moving medicine from reactive care toward predictive, personalized, and more accessible care.
• Different algorithmic approaches now serve distinct clinical roles: traditional ML remains important for structured, interpretable tasks, while deep learning dominates unstructured data such as imaging, pathology, ECG, and clinical text. Multimodal and hybrid models are increasingly favored because they combine higher diagnostic performance with practical deployment efficiency.
• Medical imaging is the most mature area of implementation, with AI improving triage, reducing diagnostic errors, and supporting faster reporting in radiology, cardiology, dermatology, and oncology. Examples in the text include melanoma detection outperforming average dermatologist sensitivity, ECG-based cardiac dysfunction models reaching AUC around 0.965, and AI-supported skin lesion assessment tools such as DermaSensor.
• AI is also reshaping drug discovery, precision medicine, and hospital operations by accelerating molecular design, improving trial stratification, tailoring therapy through pharmacogenomics and multimodal oncology models, and reducing administrative burden through ambient medical scribes. Operationally, ML supports sepsis prediction, readmission risk assessment, smart triage, and measurable reductions in physician burnout.
• The main constraints on wider adoption are regulatory, legal, and ethical rather than technical. The text emphasizes high-risk regulation under the EU AI Act, evolving FDA oversight, unresolved liability issues, and the need to address bias, explainability, cybersecurity, and data governance to enable safe human-machine collaboration in healthcare through 2030.

Evolution of Computational Architectures in the Medical Ecosystem

The foundation of the healthcare revolution lies in the diversity of algorithmic approaches, each finding specific application depending on the type of data being analyzed and the clinical requirements. Traditional machine learning techniques — such as support vector machines (SVM), random forests, and logistic regression — remain indispensable in scenarios operating on structured datasets of a smaller scale, where model interpretability and clarity of feature representation are priorities. These models are routinely applied to metabolic risk classification, prediction of compound toxicity in preclinical phases, and assessment of dosage stability for drugs such as warfarin based on genetic and clinical parameters.

In parallel, the development of deep learning (DL) neural networks has opened the door to analysis of unstructured data, such as radiological images, histopathological slides, and electrophysiological signals. Convolutional neural networks (CNNs) have come to dominate the imaging domain, enabling automatic extraction of hierarchical features from raw image files — eliminating the need for manual design of visual descriptors.

Recurrent architectures (RNNs) and modern attention-based models (Transformers) have become pivotal in analyzing sequential data — from real-time ECG signal monitoring to natural language processing (NLP) for extracting information from clinical notes.

It is worth highlighting the growing role of hybrid approaches that combine the representational power of deep learning with classical efficiency. For example, using neural networks to extract features from medical images and then subjecting them to analysis by traditional classifiers allows for a better balance between precision and computational requirements — particularly relevant in point-of-care devices with limited processing power.

Transformation of Medical Imaging: Radiology, Dermatology, and Oncology

Medical imaging represents the most mature field of ML exploitation in medicine. In radiology, AI algorithms serve as early warning systems (triage tools), automatically flagging examinations in which critical anomalies have been detected — such as tumors, intracranial hemorrhages, or pulmonary embolisms. This approach allows radiologists to focus their attention on the most complex cases while routine tasks are supported by machines, reducing report turnaround time by up to 30%.

Thoracic Radiology and Cardiothoracic Surgery

The application of ML in thoracic surgery and postoperative care has given rise to a paradigm of real-time diagnostics. Algorithms analyzing imaging data from computed tomography (CT) and magnetic resonance imaging (MRI) demonstrate the ability to identify pathological features invisible to the human eye, enabling a 20–30% reduction in diagnostic errors. In lung cancer research, deep learning networks consistently outperform traditional methods in detecting small-diameter nodules, achieving accuracy of 85% in predicting postoperative complications such as anastomotic leaks and infections.

Breakthrough in Cardiology: ECG Signal Analysis and Echocardiography

Cardiology is currently experiencing a revolution driven by ML models capable of interpreting electrocardiographic (ECG) signals with precision that sometimes surpasses that of certified cardiologists. Central to this evolution is the detection of subclinical cardiac dysfunction. Models such as DenseNet-121, trained on datasets exceeding 136,000 ECG-echocardiogram pairs, achieve area under the ROC curve (AUC) values of approximately 0.965.

Dermatology and Melanoma Detection

In dermatology, the fight against skin cancer has gained a powerful ally in the form of deep neural networks analyzing dermoscopic images. Comparative studies involving 58 experts from 17 countries showed that CNNs were able to diagnose 95% of melanoma cases, while dermatologists achieved an average sensitivity of 86.6%. Notably, AI showed less tendency to misdiagnose benign nevi as malignant, enabling the avoidance of thousands of unnecessary biopsies annually.

In 2024, the FDA approved the groundbreaking DermaSensor device — a handheld scanner using light spectroscopy and AI that allows primary care physicians to immediately evaluate skin lesions with 96% sensitivity. This solution addresses the problem of long specialist waiting times, enabling rapid identification of patients requiring urgent intervention.

Innovations in Pharmaceutical Research and Drug Design

Drug discovery has traditionally been regarded as one of the most difficult and costly areas of medicine. The application of ML in this sector is changing this trend through a radical acceleration of early research phases.

Molecular Design

The greatest breakthrough of recent years has been the introduction of systems that can predict the three-dimensional structure of proteins and their interactions with other molecules with atomic-level accuracy. This capability allows scientists to design targeted inhibitors and agonists without the need to conduct tens of thousands of trial-and-error experiments. ML algorithms trained on vast chemical libraries are able to identify optimal drug candidates while simultaneously predicting their ADMET profile (absorption, distribution, metabolism, excretion, and toxicity) at the in silico stage.

The impact of ML extends beyond molecule design. In clinical trials, AI is used to optimize protocols, predict outcomes based on early biomarkers, and precisely stratify patients — increasing the likelihood of therapeutic success. For example, drugs developed with AI support achieved a Phase I trial success rate of 80–90%, compared to the market average of approximately 40%.

Read more: Business Intelligence in Healthcare Industry: Applications and Impact

Precision Medicine and Therapy Personalization

The concept of bespoke medicine (personalized medicine) rests on the premise that every medical intervention should be tailored to the unique genetic profile, lifestyle, and environment of the patient. ML is the key tool enabling the operationalization of this approach through the integration of multi-omic data.

Pharmacogenomics and Treatment Response Prediction

Pharmacogenomics uses ML algorithms to analyze genetic variants affecting drug metabolism. Systems such as Sherpa Rx, integrated with pharmacogenomic knowledge bases, allow for appropriate drug dosing (e.g., warfarin or selective serotonin reuptake inhibitors) in a manner that minimizes the risk of serious adverse events. These models demonstrate accuracy in identifying patients who will respond to a specific oncological therapy, enabling the avoidance of toxic and ineffective treatments.

Multimodal Integration in Oncology

Contemporary oncology increasingly relies on multiple data types rather than a single examination. Multimodal models synthesize data from:

• Genomics and transcriptomics: Identification of driver mutations and gene expression profiles.
• Imaging (Radiomics): Detection of tumor phenotypic features at the macro scale.
• Digital pathology (Pathomics): Analysis of tissue structure at the cellular level.
• EHRs and Real-World Data (RWD): Analysis of disease progression in patients with similar profiles.

The MuMo model, applied in gastric cancer, integrates CT images with histological slides and clinical data, offering an AUC of 0.914 for combination therapies. Such precision allows for the creation of dynamic treatment plans that are adjusted in real time based on monitored vital parameters and biomarkers.

Operational Efficiency: EHRs, Burnout, and Hospital Triage

Beyond direct diagnostics, ML plays a fundamental role in optimizing the functioning of medical institutions. One of the most pressing problems is the administrative burden on physicians, who spend a significant portion of their time completing electronic health records (EHRs).

Ambient Medical Scribes and LLMs

The introduction of “ambient medical scribes” based on large language models (LLMs) has revolutionized the physician-patient interaction. Systems that automatically record the consultation and generate a structured clinical note ready for approval. Studies conducted in 2025 showed that deploying these tools reduced physician burnout rates from 51.9% to 38.8% within just 30 days.

Resource Management and Critical Event Prediction

ML has broad applications in patient flow management and adverse event prediction:

• Sepsis prediction: Algorithms analyzing trends in vital parameters in real time can alert staff to an impending septic shock hours in advance.
• Hospital readmissions: Models based on Gradient Boosting achieve high precision (R² = 0.81) in identifying high-risk patients for return to hospital within 30 days of discharge.
• Smart triage in emergency medicine: IoT systems integrated with ML allow for patient categorization en route, transmitting critical data to the emergency department — minimizing treatment delays.

ML Implementation in Poland: Current State and Perspectives

The Polish healthcare sector shows significant momentum in adopting AI solutions. According to a report from the Centre for e-Health, in 2024 already 13.2% of Polish hospitals were using AI-supported tools — a dramatic increase compared to 2023 (6.5%). The largest share of implementations concerns medical imaging diagnostics and administrative process automation.

Funding Mechanisms and Strategic Projects

The key impulse for ML development in Poland is support from European and national funds:

• National Recovery Plan (KPO): Investments in e-health and medical data analysis. The year 2026 is critical for settling accounts on projects automating patient registration using voicebots, directly supporting the country’s digitalization milestones.
• FENiKS Programme: Financing of modern equipment integrated with AI systems for large healthcare entities.
• Regional Operational Programmes: Support for smaller facilities and local innovations, such as the “Lublin Digital Union,” which implements AI projects in rare disease diagnostics in ophthalmology.
• Medical Fund: Priority given to projects integrating dispersed medical data and improving digital security.

Polish centers, such as the University Clinical Centre in Gdańsk, are actively participating in research on AI models in drug discovery, positioning the country as a significant player in the European medical innovation ecosystem.

Regulatory Frameworks and Ethical-Legal Challenges

The rapid advancement of ML in medicine has forced a response from regulators. In 2024 and 2025, two main oversight systems took shape: the American (FDA) and the European (EU AI Act).

FDA and Software Lifecycle Management

The FDA has taken steps to make the certification process for AI devices more flexible, appointing its first Chief AI Officer in 2025. A key instrument is Predetermined Change Control Plans (PCCPs), which allow manufacturers to pre-authorize learning algorithms — enabling software to evolve after market launch without requiring a full regulatory review after each training data update.

European Union: AI Act and High-Risk Classification

In the EU, most AI-based medical systems have been classified as “high risk” (Annex II). The Artificial Intelligence Act (AI Act), which entered into force in August 2024, imposes a range of obligations on manufacturers and deployers:

• Data governance: Ensuring high-quality training datasets to minimize bias.
• Transparency and explainability (Explainable AI — XAI): The ability to reconstruct the model’s decision-making processes, especially in cases of erroneous diagnoses.
• Human oversight: Mandatory human-in-the-loop participation in decision-making.
• Cybersecurity: Protection of AI systems against adversarial attacks that may mislead diagnostic algorithms.

Civil Liability and Medical Error

The greatest barrier to widespread AI deployment remains ambiguity around legal responsibility. In a WHO study from 2025, 86% of countries identified legal uncertainty as the primary obstacle to technology adoption. The solution is intended to be the new Product Liability Directive (PLD) in the EU, which treats AI software as a product subject to strict liability. If a patient suffers harm as a result of an erroneous AI diagnosis, they may seek compensation directly from the manufacturer, with the burden of proof eased in favor of the injured party.

One of the key ethical challenges remains “algorithmic bias.” If a model has been trained on data disproportionately representing a particular ethnic or age group, it may perform worse for other patients. An example is the underdiagnosis of liver disease in women by systems trained primarily on male datasets. Ensuring fairness therefore requires the use of diversified datasets and continuous monitoring of model performance across different population subgroups.

Read more: Scaling Behavioral Health Platform to Drive 8× Revenue Growth

Summary and Vision for the Future to 2030

The contemporary landscape of medicine in the years 2021–2026 shows that machine learning has ceased to be an experimental technology and has become a cornerstone of modern healthcare. This transformation is occurring at three levels: diagnostic, research, and operational. I

n diagnostics, ML delivers precision previously unavailable to human perception; in research, it compresses decades of laboratory work into months of in silico analysis; and in operations, it rescues systems from staffing collapse through intelligent automation.

The key conclusions drawn from analysis of the current state of knowledge point to:

• The dominance of multimodal models: The highest diagnostic value comes from combining imaging, genomics, and textual data, enabling full understanding of the patient’s biological heterogeneity.
• The necessity of Explainable AI: Building trust among clinicians and patients requires a move away from “black box” models toward systems that can justify their recommendations in a manner comprehensible to the physician.
• A new model of responsibility: The evolution of law toward a Shared Responsibility Framework among developer, hospital, and physician is essential for the safe development of the technology.
• Democratization through AI: Point-of-care tools and automated triage have the potential to level the playing field in access to specialist diagnostics, especially in regions with lower concentrations of medical personnel.

In the coming years, medicine will evolve toward a “human-machine symbiosis,” in which artificial intelligence does not replace the physician but becomes their “extended intellect” — allowing them to focus on what matters most in medicine: the relationship with the patient and the ethical dimension of healing.

The success of this transformation depends, however, on whether it will be possible to create global data governance frameworks that balance the need for innovation with the patient’s right to privacy and security.

This article was originally published on Jun 4, 2020, and was recently updated on Apr 3, 2026, to incorporate new information, case studies in metrics, and future predictions. There were also TL;DR and FAQ sections added.

Sources